Clearside Biomedical (CLSD) Misses Q2 EPS by 1c

Clearside Biomedical (NASDAQ: CLSD) reported Q2 EPS of ($0.15), $0.01 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $1.02 million versus the consensus estimate of $111.83 thousand.

For earnings history and earnings-related data on Clearside Biomedical (CLSD) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Is Treasury selloff a major issue for stock market bulls?
• DA Davidson Reiterates Buy Rating on Boost Run (BRUN)